<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006273.pub3" GROUP_ID="SYMPT" ID="024606032716361645" MERGED_FROM="" MODIFIED="2015-05-08 15:13:36 +0100" MODIFIED_BY="[Empty name]" REVIEW_NO="150" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2015-05-08 15:13:36 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-08-06 14:57:37 +0100" MODIFIED_BY="Laila Tyrrell">Medically assisted hydration for adult palliative care patients</TITLE>
<CONTACT>
<PERSON ID="49B538D082E26AA2000C5DBB71393662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Phillip</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Good</LAST_NAME>
<SUFFIX>MBBS FRACP FAChPM PhD</SUFFIX>
<POSITION>Senior Specialist</POSITION>
<EMAIL_1>Phillip.Good@svha.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Mater Research Institute &#8211; The University of Queensland</ORGANISATION>
<ADDRESS_1>411 Main Street</ADDRESS_1>
<ADDRESS_2>Kangaroo Point</ADDRESS_2>
<CITY>Brisbane</CITY>
<ZIP>4169</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 3240 1111</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 3240 1192</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-05-08 15:13:05 +0100" MODIFIED_BY="Anna Hobson">
<PERSON ID="49B538D082E26AA2000C5DBB71393662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Phillip</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Good</LAST_NAME>
<SUFFIX>MBBS FRACP FAChPM PhD</SUFFIX>
<POSITION>Senior Specialist</POSITION>
<EMAIL_1>Phillip.Good@svha.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Mater Research Institute &#8211; The University of Queensland</ORGANISATION>
<ADDRESS_1>411 Main Street</ADDRESS_1>
<ADDRESS_2>Kangaroo Point</ADDRESS_2>
<CITY>Brisbane</CITY>
<ZIP>4169</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 3240 1111</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 3240 1192</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1312051401228969534178193205451" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Russell</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Richard</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>russell.richard@svha.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>St Vincent&#8217;s Private Hospital</ORGANISATION>
<ADDRESS_1>411 Main Street</ADDRESS_1>
<ADDRESS_2>Kangaroo Point</ADDRESS_2>
<CITY>Brisbane</CITY>
<ZIP/>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61732401337</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1312051403241318402735043495680" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>William</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Syrmis</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>william.syrmis@svha.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>St Vincent&#8217;s Private Hospital</ORGANISATION>
<ADDRESS_1>411 Main Street</ADDRESS_1>
<ADDRESS_2>Kangaroo Point</ADDRESS_2>
<CITY>Brisbane</CITY>
<ZIP/>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61732401165</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15245" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Sue</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jenkins-Marsh</LAST_NAME>
<SUFFIX/>
<POSITION>Research Manager</POSITION>
<EMAIL_1>suejenksman@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>61431990290</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>The Townsville Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Townsville</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61431990290</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1312051406540131899820005906445" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Jane</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Stephens</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jane.stephens@svha.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>St Vincent&#8217;s Private Hospital</ORGANISATION>
<ADDRESS_1>411 Main Street</ADDRESS_1>
<ADDRESS_2>Kangaroo Point</ADDRESS_2>
<CITY>Brisbane</CITY>
<ZIP/>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-04-17 11:16:16 +0100" MODIFIED_BY="Anna Hobson">
<UP_TO_DATE>
<DATE DAY="26" MONTH="3" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="3" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="3" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2015-05-08 15:13:36 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2015-05-08 15:13:36 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>This review will be assessed for further updating in 2019.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-05-08 15:13:21 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-05-08 15:13:19 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="4" YEAR="2014"/>
<DESCRIPTION>
<P>The search for this review was re-run in April 2013 and March 2014. No new studies were found. Minor change to conclusions. We recommend that readers of the original review read this latest version.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-05-08 15:13:21 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>We added a PRISMA flowchart to document the study selection process and added risk of bias tables.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-01-09 14:18:13 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="14" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>The search for this review was re-run in February 2011. No new studies were identified to be included in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-02-14 10:11:26 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-06 16:56:16 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="6" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-03-26 11:06:27 +0000" MODIFIED_BY="Anna Hobson">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2014-03-26 11:06:27 +0000" MODIFIED_BY="Anna Hobson">
<SOURCE MODIFIED="2014-03-26 11:06:27 +0000" MODIFIED_BY="Anna Hobson">
<NAME>National Institute for Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>NIHR Directly Commissioned Cochrane Incentive Scheme 2013 Award Reference Number 13/180/04.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-04-17 11:18:50 +0100" MODIFIED_BY="Anna Hobson">
<SUMMARY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<TITLE>Medically assisted hydration to assist palliative care patients</TITLE>
<SUMMARY_BODY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>
<B>Background</B>
</P>
<P>It is common for palliative care patients to have reduced fluid intake during their illness. Management of this condition includes discussion with the patient, family and staff involved, and may include the provision of fluids with medical assistance. This can be performed using a small plastic tube inserted into a vein or under the skin, or via a tube inserted into the stomach. It is unknown whether this treatment helps people to feel better or live longer.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We searched the international literature for randomised controlled trials looking at the effects of medically assisted hydration in adults receiving palliative care. Randomised controlled trials allocate patients to one of two or more treatment groups in a random manner and provide the most accurate information on the best treatment. We conducted the searches in April 2013 and March 2014.</P>
<P>
<B>Key results and quality of evidence</B>
</P>
<P>We found only six studies looking at this issue. The studies did not show a significant benefit in the use of medically assisted hydration in palliative care patients; however, there are insufficient good-quality studies to make any definitive recommendations. . As a result, it is not possible to define the benefits and harms of this treatment clearly.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-04-16 14:06:40 +0100" MODIFIED_BY="Anna Hobson">
<ABS_BACKGROUND MODIFIED="2014-03-26 11:32:14 +0000" MODIFIED_BY="Anna Hobson">
<P>Many palliative care patients have reduced oral intake during their illness. The management of this can include the provision of medically assisted hydration with the aim of prolonging the life of a patient, improving their quality of life, or both. This is an updated version of the original Cochrane review published in Issue 2, 2008, and updated in February 2011.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effect of medically assisted hydration in palliative care patients on their quality and length of life.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-04-16 14:06:40 +0100" MODIFIED_BY="Anna Hobson">
<P>We identified studies by searching the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, CANCERLIT, Caresearch, Dissertation abstracts, SCIENCE CITATION INDEX and the reference lists of all eligible studies, key textbooks and previous systematic reviews. The date of the latest search conducted on CENTRAL, MEDLINE and EMBASE was March 2014.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All relevant randomised controlled trials (RCTs) or prospective controlled studies of medically assisted hydration in palliative care patients.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>We identified six relevant studies for this update. These included three RCTs (222 participants), and three prospective controlled trials (360 participants). Two review authors independently assessed the studies for quality and validity. The small number of studies and the heterogeneity of the data meant that a quantitative analysis was not possible, so we included a description of the main findings.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>One study found that sedation and myoclonus (involuntary contractions of muscles) scores were improved more in the intervention group. Another study found that dehydration was significantly higher in the non-hydration group, but that some fluid retention symptoms (pleural effusion, peripheral oedema and ascites) were significantly higher in the hydration group. The other four studies (including the three RCTs) did not show significant differences in outcomes between the two groups. The only study that had survival as an outcome found no difference in survival between the hydration and control arms.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Since the last version of this review, we found one new study. The studies published do not show a significant benefit in the use of medically assisted hydration in palliative care patients; however, there are insufficient good-quality studies to inform definitive recommendations for practice with regard to the use of medically assisted hydration in palliative care patients.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-04-17 11:18:50 +0100" MODIFIED_BY="Anna Hobson">
<BACKGROUND MODIFIED="2014-04-17 11:18:50 +0100" MODIFIED_BY="Anna Hobson">
<P>This review is an update of a previously published review in the <I>Cochrane Database of Systematic Reviews</I> (Issue 2, 2008) on "Medically assisted hydration for adult palliative care patients" (<LINK REF="REF-Good-2008" TYPE="REFERENCE">Good 2008</LINK>).</P>
<CONDITION MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Many palliative care patients have a reduced oral intake during their illness. The cause of this varies, but may be due partly to a physical obstruction, anorexia/cachexia syndrome, generalised weakness, bowel obstruction, nausea, decreased level of consciousness, loss of desire to drink or no specific cause may be identified. The most common time for this decreased oral intake is during the terminal phase, when the patient becomes less conscious and, therefore, less able to receive fluids orally (<LINK REF="REF-Morita-1998" TYPE="REFERENCE">Morita 1998</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Management of this condition includes discussion with the patient, family and staff involved, and either no medical intervention (but continued attention to treating any symptomatic problems, including good mouth care) or the provision of hydration with medical assistance. Medically assisted hydration is usually performed via the intravenous or subcutaneous routes (parenteral), but can also use the gastrointestinal system (enteral). There is great variation in practice with regards to hydration. For example, <LINK REF="REF-Lanuke-2003" TYPE="REFERENCE">Lanuke 2003</LINK> found that the rate of provision of medically assisted hydration differed greatly across Canada (range 0% to 100%).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>The aim of medically assisted hydration can be to prolong the length of life of a patient, improve their quality of life (QoL), or both. These benefits may come via the reversal of the physiological factors associated with the patient's decline. Balanced against these potential benefits are adverse events that can be associated with any intervention (infection, bleeding, pain, etc.) (<LINK REF="REF-Bozzetti-1996" TYPE="REFERENCE">Bozzetti 1996</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-04-17 11:17:25 +0100" MODIFIED_BY="Anna Hobson">
<P>There is controversy about the ethical aspects of medically assisted hydration (<LINK REF="REF-Casarett-2005" TYPE="REFERENCE">Casarett 2005</LINK>). The first ethical controversy centres on whether medically assisted hydration is a medical intervention or a basic provision of comfort. Second, there is controversy as to how and by whom decisions should be made with regards to medically assisted hydration in patients who no longer have the capacity to make decisions for themselves. This review will concentrate on assessing the benefit of provision of hydration with medical assistance versus the harm caused by such intervention in palliative care patients. It is only with this information that clinicians and patients can make informed decisions about whether this type of intervention is beneficial or harmful to an individual patient.<BR/>
<BR/>There is a separate review considering medically assisted nutrition for palliative care patients (<LINK REF="REF-Good-2014" TYPE="REFERENCE">Good 2014</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>To determine the effect of medically assisted hydration in palliative care patients on their QoL and length of life.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-04-16 13:31:22 +0100" MODIFIED_BY="Anna Hobson">
<SELECTION_CRITERIA MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<CRIT_STUDIES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>All relevant randomised controlled trials (RCTs) or prospective controlled studies that fulfilled the inclusion criteria.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Participants included:<BR/>
</P>
<UL>
<LI>palliative care participants who received medically assisted hydration;</LI>
<LI>patients receiving palliative care (<LINK REF="REF-WHO-2005" TYPE="REFERENCE">WHO 2005</LINK>);</LI>
<LI>(but were not limited to) incurable cancer, dementia, neurodegenerative diseases (e.g. motor neuron disease), human immunodeficiency virus, chronic airways limitation and chronic heart failure;</LI>
<LI>whose prognosis was limited and the focus of care was QoL (<LINK REF="REF-Doyle-2004" TYPE="REFERENCE">Doyle 2004</LINK>); and</LI>
<LI>adults aged 18 years and above, both male and female and in any setting such as home, hospice or hospital.</LI>
</UL>
<P>We did not limit included participants to those in the terminal phase of their illness. We excluded participants who were having medically assisted hydration as part of a perioperative, chemotherapy or radiotherapy regimen, or because of chemotherapy or radiotherapy adverse effects.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="4">Medically assisted administration of fluids</HEADING>
<UL>
<LI>Medically assisted hydration - administration of non-nutritional fluids, administered via the subcutaneous tissue, venous system or enterally (nasogastric tube, jejunostomy, gastrostomy).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparisons</HEADING>
<UL>
<LI>Placebo.</LI>
<LI>No intervention.</LI>
<LI>Usual treatment or supportive care.</LI>
</UL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<OL>
<LI>QoL on any measure (including symptom assessment scales).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<OL>
<LI>Survival.</LI>
<LI>Adverse events.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-04-16 13:31:22 +0100" MODIFIED_BY="Anna Hobson">
<P>
<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2014-04-16 13:31:22 +0100" MODIFIED_BY="Anna Hobson">
<P>We searched the following electronic databases using a search strategy developed for MEDLINE via Ovid, but were modified appropriately for each database. See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the search strategies.<BR/>
</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (searched up to Issue 2, 2014).</LI>
<LI>MEDLINE (Ovid) (1966 to 25/03/2014).</LI>
<LI>EMBASE (Ovid) (1980 to 25/03/2014).</LI>
<LI>SCIENCE CITATION INDEX (ISI Web of Science) (1900 to March 2014).</LI>
<LI>CINAHL (EBSCO) (1982 to March 2014).</LI>
<LI>CANCERLIT (up to February 2008).</LI>
<LI>Caresearch - database listing conference proceedings and grey literature (up to February 2008).</LI>
<LI>Dissertation abstracts (up to February 2008).</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="4">Reference lists</HEADING>
<P>We searched the reference lists of all eligible studies, key textbooks and previous systematic reviews for additional studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Language</HEADING>
<P>The search attempted to identify all relevant studies irrespective of language. We found no non-English papers.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<STUDY_SELECTION MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>The original search was performed in October 2006, and repeated in February 2008. A further search was performed in November 2010 for the first update. The original review included five studies, with no new studies added for the first update. We performed subsequent searches in April 2013 and March 2014 for the update of this review (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). From this search, we reviewed the titles and abstracts and retrieved publications of eight studies in full. After review of these articles, seven did not meet the inclusion criteria, leaving one new study for inclusion (in addition to the five studies from original review and update).<B>
<I>
<BR/>
</I>
</B>
</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="4">Data extraction</HEADING>
<P>We obtained the following information for each study:</P>
<OL>
<LI>study methods (study design, allocation, blinding, setting, inclusion criteria);</LI>
<LI>participants (sample size, exclusions/inclusions, number, disease, duration of study, withdrawals and drop-outs, site - e.g. hospital, hospice, home);</LI>
<LI>intervention (type, route of delivery, control used);</LI>
<LI>outcome (QoL, symptom measures, survival, time from death intervention was initiated); and</LI>
<LI>adverse effects.</LI>
</OL>
<P>All review authors extracted this information independently, and agreed the final data by consensus.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Data analysis</HEADING>
<P>We planned to pool results had there been sufficient data and homogeneity between studies. However, we identified only three RCTs, and only a small number of participants were recruited to these studies. The heterogeneity of the data meant that a quantitative analysis was not possible. A description of the main findings from the studies is presented in the <LINK TAG="RESULTS" TYPE="SECTION">Results</LINK> section.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="4">Quality</HEADING>
<P>We assessed the methodological quality of the six studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Assessment of risk of bias in included studies</HEADING>
<P>For this update, we continued to assess quality using the Oxford Quality Scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>), which allocates points for randomisation, blinding and the recording of study withdrawals. This scale uses the following questions to rate the likelihood of bias (the higher the score the less likelihood of bias, scale of zero to five).</P>
<OL>
<LI>Was the study described as randomised (one = yes; zero = no)?</LI>
<LI>Was the study described as double blind (one = yes; zero = no)?</LI>
<LI>Was there a description of withdrawals and drop-outs (one = yes; zero = no)?</LI>
<LI>Was the method of randomisation well described and appropriate (one = yes; zero = no)?</LI>
<LI>Was the method of double-blinding well described and appropriate (one = yes; zero = no)?</LI>
<LI>Deduct one point each if methods for randomisation and blinding were inappropriate.</LI>
</OL>
<P>Scoring system: maximum score = five; minimum score = zero.</P>
<P>The maximum possible score (indicating a trial of high methodological quality) is five.</P>
<P>Three studies were prospective controlled trials and their methodology was assessed using a scale devised by Rinck et al. (<LINK REF="REF-Rinck-1997" TYPE="REFERENCE">Rinck 1997</LINK>).</P>
<OL>
<LI>Quality criteria - accrual of the study population.</LI>
<LI>Homogeneity and participant characteristics.</LI>
<LI>Randomisation.</LI>
<LI>Attrition and sample size.</LI>
<LI>Interventions.</LI>
<LI>Outcome measurement.</LI>
<LI>Presentation of results.</LI>
</OL>
<P>Score one point if criteria fully applied.<BR/>Score 0.5 point if criteria was not fully applied.<BR/>Score zero if criteria (mostly) not applied.<BR/>Scoring system: maximum score = seven, minimum score = zero.</P>
<P>For this update, we also used the Cochrane 'Risk of bias' tool. We completed a 'Risk of bias' table for each included study, using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We assessed the following for each study:</P>
<OL>
<LI>Random sequence generation (checking for selection bias).</LI>
<LI>Allocation concealment (checking for selection bias).</LI>
<LI>Blinding of participants and personnel (checking for performance bias).</LI>
<LI>Blinding of outcome assessment (checking for detection bias).</LI>
<LI>Incomplete outcome data (checking for attrition bias).</LI>
<LI>Selective reporting (checking for reporting bias).</LI>
<LI>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (&#8805; 200 participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (&lt; 50 participants per treatment arm).</LI>
</OL>
<P>The results for each included study are reported in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-04-16 13:53:17 +0100" MODIFIED_BY="Anna Hobson">
<STUDY_DESCRIPTION MODIFIED="2014-04-16 13:53:17 +0100" MODIFIED_BY="Anna Hobson">
<P>The searches for this update were run in April 2013 and March 2014, which identified one new RCT (<LINK REF="STD-Bruera-2013" TYPE="STUDY">Bruera 2013,</LINK> 129 participants) (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for details of the study selection process). In addition to this new study were the original five studies in which two were RCTs (<LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK>, 51 participants; <LINK REF="STD-Cerchietti-2000" TYPE="STUDY">Cerchietti 2000</LINK>, 42 participants), and three were prospective controlled trials (<LINK REF="STD-Morita-2005" TYPE="STUDY">Morita 2005</LINK>, 226 participants; <LINK REF="STD-Waller-1994" TYPE="STUDY">Waller 1994</LINK>, 68 participants; <LINK REF="STD-Viola-1997" TYPE="STUDY">Viola 1997</LINK>, 66 participants). For the original search, seven studies appeared to meet the inclusion criteria (<LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK>; <LINK REF="STD-Cerchietti-2000" TYPE="STUDY">Cerchietti 2000</LINK>; <LINK REF="STD-Morita-2002" TYPE="STUDY">Morita 2002</LINK>; <LINK REF="STD-Morita-2005" TYPE="STUDY">Morita 2005</LINK>; <LINK REF="STD-Morita-2006" TYPE="STUDY">Morita 2006</LINK>; <LINK REF="STD-Waller-1994" TYPE="STUDY">Waller 1994</LINK>; <LINK REF="STD-Viola-1997" TYPE="STUDY">Viola 1997</LINK>). On further review, two studies were excluded (<LINK REF="STD-Morita-2002" TYPE="STUDY">Morita 2002</LINK>; <LINK REF="STD-Morita-2006" TYPE="STUDY">Morita 2006</LINK>). One study was excluded because there were no comparisons between the groups with regards to hydration (<LINK REF="STD-Morita-2002" TYPE="STUDY">Morita 2002</LINK>). The second study was excluded because there was no comparison between the symptoms of the hydrated and non-hydrated groups (<LINK REF="STD-Morita-2006" TYPE="STUDY">Morita 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Study design</HEADING>
<P>Three studies had an RCT design (<LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK>; <LINK REF="STD-Bruera-2013" TYPE="STUDY">Bruera 2013</LINK>;
 

<LINK REF="STD-Cerchietti-2000" TYPE="STUDY">Cerchietti 2000</LINK>). The study intervention of these was for two days (<LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK>; <LINK REF="STD-Cerchietti-2000" TYPE="STUDY">Cerchietti 2000</LINK>) or "until the patient was unresponsive, developed progressive coma, or died" (<LINK REF="STD-Bruera-2013" TYPE="STUDY">Bruera 2013</LINK>). The other three studies had a prospective controlled trial design (<LINK REF="STD-Morita-2005" TYPE="STUDY">Morita 2005</LINK>;
 

<LINK REF="STD-Waller-1994" TYPE="STUDY">Waller 1994</LINK>; <LINK REF="STD-Viola-1997" TYPE="STUDY">Viola 1997</LINK>). The study conducted in Japan by <LINK REF="STD-Morita-2005" TYPE="STUDY">Morita 2005</LINK> had a study duration of three weeks, while the study by <LINK REF="STD-Waller-1994" TYPE="STUDY">Waller 1994</LINK> was from admission to a hospice until death and <LINK REF="STD-Viola-1997" TYPE="STUDY">Viola 1997</LINK> was from enrolment in the study until death, discharge or no longer having a fluid deficit.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Study population</HEADING>
<P>All of the studies included only participants with advanced cancer. Four studies only included participants in whom it was thought the participants were dehydrated (<LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK>; <LINK REF="STD-Bruera-2013" TYPE="STUDY">Bruera 2013</LINK>; <LINK REF="STD-Cerchietti-2000" TYPE="STUDY">Cerchietti 2000</LINK>; <LINK REF="STD-Viola-1997" TYPE="STUDY">Viola 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intervention</HEADING>
<P>All of the studies aimed to administer at least 1000 mL of fluid per day to the intervention group. The route of this varied between intravenous and subcutaneous.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>The outcomes measured in all the studies were very different.</P>
<UL>
<LI>
<LINK REF="STD-Waller-1994" TYPE="STUDY">Waller 1994</LINK> only considered the state of consciousness.</LI>
<LI>
<LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK> had a main outcome measure as the global assessment of the overall benefit of hydration to the participant, as determined by the physician and participant on day two. This was supplemented by a number of secondary outcome measures. These included symptom assessment scales used for sedation, fatigue, hallucinations, myoclonus, symptoms totalled together and the Mini Mental Status Examination (MMSE). These symptoms were scored on a numerical rating of zero to 10 scale, with a decrease of one point indicating an improvement (this was defined by the authors and it is unclear whether this is a statistical or clinical improvement).</LI>
<LI>The RCT by <LINK REF="STD-Bruera-2013" TYPE="STUDY">Bruera 2013</LINK> had the primary outcome as the change in the sum of four dehydration symptoms (fatigue, myoclonus, sedation and hallucinations) between day four and baseline. Secondary outcome measures included delirium (Memorial Delirium Assessment Scale (MDAS), Richmond Agitation Sedation Scale (RASS) Nursing Delirium Screening Scale (NuDESC)), change in the sum of four dehydration symptoms (fatigue, myoclonus, sedation and hallucinations) between day seven and baseline, global symptom evaluation, QoL using Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) and Functional Assessment of Chronic Illness Therapy - General (FACIT-G), hydration status using a dehydration assessment scale and survival.</LI>
<LI>
<LINK REF="STD-Cerchietti-2000" TYPE="STUDY">Cerchietti 2000</LINK> primarily studied the symptoms of thirst, chronic nausea, delirium and changes in MMSE. Secondary outcome measures included anguish and mood.</LI>
<LI>The observational study of <LINK REF="STD-Morita-2005" TYPE="STUDY">Morita 2005</LINK> examined dehydration, fluid retention (ascites, bronchial secretions, peripheral oedema), hyperactive delirium, myoclonus, bedsores, agitation and communication capacity.</LI>
<LI>
<LINK REF="STD-Viola-1997" TYPE="STUDY">Viola 1997</LINK> studied the prevalence of multiple physical symptoms and cognition.</LI>
<LI>Two RCTS examined adverse effects of medically assisted hydration including local adverse effects (discomfort, pain, infection, oedema, erythema, bleeding at the puncture site) and interruption of hydration due to adverse effects (oedema, increase in respiratory secretions, congestive heart failure) (<LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK>; <LINK REF="STD-Cerchietti-2000" TYPE="STUDY">Cerchietti 2000</LINK>).</LI>
</UL>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>All review authors assessed the included studies using two different quality scales. We assessed the three RCTs using the Oxford Quality Scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). Two of the RCTs scored five out of five on this scale, as they were well-designed and well-performed studies (<LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK>; <LINK REF="STD-Bruera-2013" TYPE="STUDY">Bruera 2013</LINK>). In particular, the methods of randomisation and blinding were well described and appropriate. However, the third RCT scored only two out of five, as neither the method of randomisation nor whether any blinding was performed were described (<LINK REF="STD-Cerchietti-2000" TYPE="STUDY">Cerchietti 2000</LINK>).</P>
<P>The other three studies were prospective controlled trials and we assessed their quality using the Rinck scale (<LINK REF="REF-Rinck-1997" TYPE="REFERENCE">Rinck 1997</LINK>). One of the studies, <LINK REF="STD-Morita-2005" TYPE="STUDY">Morita 2005</LINK>, scored 4.5 out of a maximum of seven on this scale. Its strengths were that consecutive participants were asked to be enrolled and a good description of baseline characteristics and follow-up was given. However, allocation was via physician preference, thus introducing an element of bias, and there was no blinding of allocation to scoring of outcomes. The aim of the allocation according to physician preference was to try to mimic real world decision making. The study by <LINK REF="STD-Waller-1994" TYPE="STUDY">Waller 1994</LINK> was subject to many methodological problems. There was inadequate inclusion and recruitment strategy, a poorly defined control group, no baseline data presented for groups, and the length of time and composition of intravenous fluids was not included. This paper scored 1.5 out of seven on the Rinck scale. The third prospective study scored four out of seven on the Rinck scale (<LINK REF="STD-Viola-1997" TYPE="STUDY">Viola 1997</LINK>). This study was well designed, but the major shortcoming was in recruitment and performance of the study. Recruitment was performed at two different centres, and the two groups at baseline had many differences including type of cancers and symptom assessment scores. This meant that we were unable to make a true comparison between the group receiving medically assisted hydration and the control group receiving no medically assisted hydration in any of the outcome measures.</P>
<P>For this update, we incorporated the Cochrane 'Risk of bias' tool. The findings are listed in the 'Risk of bias' table in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. The overall findings are presented in the 'Risk of bias' graph (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) and the 'Risk of bias' summary (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). The two RCTs by Bruera et al. had a low risk of bias (except for size of study) (<LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK>; <LINK REF="STD-Bruera-2013" TYPE="STUDY">Bruera 2013</LINK>), while all the others had high or unclear risk across all the categories.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="3">Effectiveness</HEADING>
<P>One study found that sedation and myoclonus were more greatly improved in the intervention group (<LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK>). In addition, if the total scores for the four target symptoms (sedation, fatigue, hallucinations, myoclonus) were taken as a whole, there was more improvement in the intervention group. The secondary outcome measure used in the <LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK> study (proportion of participants perceived to have some benefit was 50% or greater) was significant in the hydration group in the view of the physicians but not the participant's viewpoint. In another study (<LINK REF="STD-Cerchietti-2000" TYPE="STUDY">Cerchietti 2000</LINK>), it was stated that "control of chronic nausea after 24 hours was significantly better in the group receiving hydration". However, the results were never tabulated, but rather presented in a graphical form, and this actually showed the two groups almost equal after 24 hours, and the non-hydration group improving more than the hydration group in terms of lowering the visual analogue score for chronic nausea. One study found that night-time delirium was worse in the control group compared with the hydration group at day four, (but not day seven) as measured by NuDESC (<LINK REF="STD-Bruera-2013" TYPE="STUDY">Bruera 2013</LINK>). There were no significant differences found in all the other outcomes examined at in five other studies in terms of effectiveness of medically assisted hydration (<LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK>; <LINK REF="STD-Bruera-2013" TYPE="STUDY">Bruera 2013</LINK>; <LINK REF="STD-Cerchietti-2000" TYPE="STUDY">Cerchietti 2000</LINK>; <LINK REF="STD-Morita-2005" TYPE="STUDY">Morita 2005</LINK>; <LINK REF="STD-Waller-1994" TYPE="STUDY">Waller 1994</LINK>). The fifth study only provided descriptive statistics, and so a comparison between the groups was not possible (<LINK REF="STD-Viola-1997" TYPE="STUDY">Viola 1997</LINK>). In the one study that had survival as an outcome measure, there was no difference between the hydration and control groups (<LINK REF="STD-Bruera-2013" TYPE="STUDY">Bruera 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>In terms of local adverse reactions, <LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK> reported no differences between the groups, but <LINK REF="STD-Cerchietti-2000" TYPE="STUDY">Cerchietti 2000</LINK> found there was one participant with erythema and pain at the puncture site in the intervention group. <LINK REF="STD-Morita-2005" TYPE="STUDY">Morita 2005</LINK> found that dehydration was significantly higher in the non-hydration group, and that some fluid retention symptoms (pleural effusion, peripheral oedema and ascites) were significantly higher in the hydration group.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-04-16 13:52:11 +0100" MODIFIED_BY="Anna Hobson">
<P>The objective of this systematic review was to determine the effect of medically assisted hydration in palliative care patients on their QoL and length of life. Extensive searching of the literature produced only six studies suitable for inclusion. This included three RCTs. Two of these were of high methodological quality, but were unable to recruit a sufficient number of participants to adequately power the studies (<LINK REF="STD-Bruera-2005" TYPE="STUDY">Bruera 2005</LINK>; <LINK REF="STD-Bruera-2013" TYPE="STUDY">Bruera 2013</LINK>), while the other had methodological flaws in design and reporting of results (<LINK REF="STD-Cerchietti-2000" TYPE="STUDY">Cerchietti 2000</LINK>). One of these studies had survival as an outcome and found no difference between the hydration and control arm (<LINK REF="STD-Bruera-2013" TYPE="STUDY">Bruera 2013</LINK>). Of the three prospective controlled studies, one was of reasonable quality (<LINK REF="STD-Morita-2005" TYPE="STUDY">Morita 2005</LINK>), while another had methodological shortcomings in design and reporting (<LINK REF="STD-Waller-1994" TYPE="STUDY">Waller 1994</LINK>). The third prospectively controlled trial had a good methodological basis, but unfortunately, the two groups recruited had many differences at baseline (<LINK REF="STD-Viola-1997" TYPE="STUDY">Viola 1997</LINK>). There was also no statistical analysis of the results to determine if any differences were significant. The participants included in these studies represent a 'narrow' palliative care population in that they all have cancer that is defined as 'advanced' or 'terminal'. It is questionable whether the results of these studies would be generalisable to a wider palliative care population, especially people who do not have cancer.</P>
<P>One study found that sedation and myoclonus (involuntary contractions of muscles) scores were improved more in the intervention group. Another study found that hydration may also cause some adverse effects in terms of fluid retention (in particular pleural effusion, peripheral oedema and ascites). However, these results must be taken within the context of low participant numbers and methodological difficulties in the studies.</P>
<P>There has been much debate and varying views about the provision of medically assisted hydration to palliative care patients (<LINK REF="REF-Ashby-1995" TYPE="REFERENCE">Ashby 1995</LINK>; <LINK REF="REF-Craig-1994" TYPE="REFERENCE">Craig 1994</LINK>;<LINK REF="REF-Dev-2012" TYPE="REFERENCE">Dev 2012</LINK>; <LINK REF="REF-Raijmakers-2011" TYPE="REFERENCE">Raijmakers 2011</LINK>). This review shows that there have been very few high-quality studies examining the symptom benefits, and adverse effects of such an intervention.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<IMPLICATIONS_PRACTICE MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Since the last version of this review, we found one new study. The studies published show no significant benefit in the use of medically assisted hydration in palliative care patients; however, there are insufficient good quality studies to inform definitive recommendations for practice with regard to the use of medically assisted hydration in palliative care patients.</P>
<P>There are a few good-quality studies that examine the benefits and harms of the use of medically assisted hydration in this population. Two randomised controlled trials (RCTs) in this review had a short duration of hydration (two days) to assess effects, and no information on the effect hydration may have on survival. The other RCT was of longer duration, and found little difference in outcomes between the hydration and control groups. It also found no difference in survival between the two groups. The results from one included study suggest that there may be some benefit in terms of improvement in sedation and myoclonus, but another study showed that there may be some harm in terms of worsening of fluid retention symptoms (pleural effusion, peripheral oedema and ascites) and these results need to be taken in the context of low participant numbers, limited palliative care settings and narrow palliative care patient population groups. Clinicians will need to make a decision based on the perceived benefits and harms of medically assisted hydration in individual patient circumstances, without the benefit of high-quality evidence to guide them.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="3">Study design</HEADING>
<P>High-quality studies in the palliative care population have proven very difficult to perform successfully. The difficulty of research in a vulnerable population such as palliative care patients has been discussed in the literature. These difficulties start with consent, are followed by recruitment, elimination of confounders and end with retention of participants throughout a study period (<LINK REF="REF-Rinck-1997" TYPE="REFERENCE">Rinck 1997</LINK>). There have been some innovative suggestions about how to overcome the issue of consent (<LINK REF="REF-Rees-2003" TYPE="REFERENCE">Rees 2003</LINK>), and some studies have used this methodology with success (<LINK REF="REF-Breitbart-2002" TYPE="REFERENCE">Breitbart 2002</LINK>). Other studies have shown that large numbers are not always needed to show a benefit (<LINK REF="REF-Abernethy-2003" TYPE="REFERENCE">Abernethy 2003</LINK>), but the question of safety is difficult to answer due to the small numbers of participants commonly being found in palliative care studies. This has been illustrated by the fact that there were only two RCTs of a high quality in this review. Despite being methodologically sound, the results were limited by lack of recruitment. Perhaps of more interest was that the issue of medically assisted hydration in palliative care patients causes such divergent views, yet there are so few studies to guide clinical practice properly. As well as examining further RCTs in this area, the evidence base will be improved with at least more prospective controlled trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participant groups</HEADING>
<P>The studies in this review had narrowly defined patient populations. Palliative care is performed in hospitals, inpatient palliative care units and in the community. Studies need to be performed in all these areas to allow external validity to different palliative care populations. It would also be helpful to define at what stage of their illness participants are being given medically assisted hydration. The reasons and aims of hydration in the last few days/weeks of life may be very different to those participants with a longer prognosis. An agreed diagnostic criteria for hydration status is essential for future trials, both to assess at entry and to assess as an outcome. In addition, all the participants in the included studies had advanced cancer, and it is important to examine medically assisted hydration in non-cancer populations. The prospective prediction of prognosis is difficult, and it may be better to stratify participants according to their performance status.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>Medically assisted hydration can be given by many different routes. The studies included in this review used either the subcutaneous or intravenous route. We found no studies that used the enteral route for hydration. Further studies are needed to determine the optimum route and dose.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>It is important that clinically relevant outcomes are clearly defined and are the most clinically useful. In this patient population, this should include symptoms (such as sedation, fatigue, hallucinations and myoclonus) as well as diagnoses such as delirium. Despite much controversy about the effect medically assisted hydration may have on length of life, it was only included as an outcome in one study in this review. Future studies should include the survival of participants as an outcome. It is equally important that adverse events are well defined so that the risk of treatment can be balanced against any benefits.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>We wish to thank the Cochrane Pain, Palliative and Supportive Care Review Group for ongoing support in updating this review.</P>
<P>John Cavenagh, Mark Mather and Peter Ravenscroft were authors on the original review but did not contribute to this update.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Phillip Good: formulated question, wrote protocol, searched for studies, reviewed titles and abstracts, retrieved articles, assessed article quality, wrote review, wrote update.</P>
<P>Russell Richard: reviewed titles and abstracts, assessed article quality, performed critical revision of review.</P>
<P>William Syrmis: reviewed titles and abstracts, assessed article quality, performed critical revision of review.</P>
<P>Sue Jenkins-Marsh: reviewed titles and abstracts, assessed article quality, performed critical revision of review.</P>
<P>Jane Stephens: reviewed titles and abstracts, assessed article quality, performed critical revision of review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-04-17 11:20:30 +0100" MODIFIED_BY="Anna Hobson">
<STUDIES MODIFIED="2014-04-16 14:06:01 +0100" MODIFIED_BY="Anna Hobson">
<INCLUDED_STUDIES MODIFIED="2014-04-16 14:06:01 +0100" MODIFIED_BY="Anna Hobson">
<STUDY DATA_SOURCE="PUB" ID="STD-Bruera-2005" MODIFIED="2014-04-03 14:44:08 +0100" MODIFIED_BY="Anne Lawson" NAME="Bruera 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-04-03 14:44:08 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;1. Bruera E, Sala R, Rico MA, Moyano J, Centeno C, Willey J, et al. Effects of parenteral hydration in terminally ill cancer patients: a preliminary study. Journal of Clinical Oncology 2005;23:2366-71.&lt;/p&gt;" NOTES_MODIFIED="2014-04-03 14:44:08 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E, Sala R, Rico MA, Moyano J, Centeno C, Willey J, et al</AU>
<TI>Effects of parenteral hydration in terminally ill cancer patients: a preliminary study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>2366-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruera-2013" MODIFIED="2014-04-16 14:06:01 +0100" MODIFIED_BY="Anna Hobson" NAME="Bruera 2013" YEAR="2010">
<REFERENCE MODIFIED="2014-04-16 14:06:01 +0100" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E, Hui D, Dalal S, Torres-Vigil I, Trumble J, Roosth J, et al</AU>
<TI>Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled randomized trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2013</YR>
<VL>21</VL>
<NO>1</NO>
<PG>111-8</PG>
<IDENTIFIERS MODIFIED="2013-12-16 06:04:12 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 06:04:12 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1200/jco.2012.44.6518"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cerchietti-2000" NAME="Cerchietti 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;2. Cerchietti L, Navigante A, Sauri A, Palazzo F. Hypodermoclysis for control of dehydration in terminal-stage cancer. International Journal of Palliative Nursing 2000;6:370-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cerchietti L, Navigante A, Sauri A, Palazzo F</AU>
<TI>Hypodermoclysis for control of dehydration in terminal-stage cancer</TI>
<SO>International Journal of Palliative Nursing</SO>
<YR>2000</YR>
<VL>6</VL>
<PG>370-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morita-2005" MODIFIED="2014-04-03 14:44:27 +0100" MODIFIED_BY="Anne Lawson" NAME="Morita 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-04-03 14:44:27 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;4. Morita T, Hyodo I, Yoshimi T, Ikenaga M, Tamura Y, Yoshizawa A, et al. Association between hydration volume and symptoms in terminally ill cancer patients with abdominal malignancies. Annals of Oncology 2005;16:640-7.&lt;/p&gt;" NOTES_MODIFIED="2014-04-03 14:44:27 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morita T, Hyodo I, Yoshimi T, Ikenaga M, Tamura Y, Yoshizawa A, et al</AU>
<TI>Association between hydration volume and symptoms in terminally ill cancer patients with abdominal malignancies</TI>
<SO>Annals of Oncology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>640-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Viola-1997" MODIFIED="2014-04-03 17:06:04 +0100" MODIFIED_BY="Anne Lawson" NAME="Viola 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-04-03 17:06:04 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="BOOK">
<AU>Viola RA</AU>
<SO>Studying Fluid Status and the Dying: The Challenge of Clinical Research in Palliative Care [MSc thesis]</SO>
<YR>1997</YR>
<PB>University of Ottawa</PB>
<CY>Canada</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waller-1994" NAME="Waller 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;6. Waller A, Hershkowitz M, Adunsky A. The effect of intravenous fluid infusion on blood and urine parameters of hydration and on state of consciousness in terminal cancer patients.[see comment]. American Journal of Hospice &amp;amp; Palliative Care 1994;11:22-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waller A, Hershkowitz M, Adunsky A</AU>
<TI>The effect of intravenous fluid infusion on blood and urine parameters of hydration and on state of consciousness in terminal cancer patients</TI>
<SO>American Journal of Hospice &amp; Palliative Care</SO>
<YR>1994</YR>
<VL>11</VL>
<PG>22-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-04-03 14:46:33 +0100" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-Morita-2002" NAME="Morita 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;5. Morita T, Tei Y, Inoue S, Suga A, Chihara S. Fluid status of terminally ill cancer patients with intestinal obstruction: an exploratory observational study. Supportive Care in Cancer 2002;10:474-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morita T, Tei Y, Inoue S, Suga A, Chihara S</AU>
<TI>Fluid status of terminally ill cancer patients with intestinal obstruction: an exploratory observational study</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2002</YR>
<VL>10</VL>
<PG>474-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morita-2006" MODIFIED="2014-04-03 14:46:33 +0100" MODIFIED_BY="Anne Lawson" NAME="Morita 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-04-03 14:46:33 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;3. Morita T, Hyodo I, Yoshimi T, Ikenaga M, Tamura Y, Yoshizawa A, et al. Artificial hydration therapy, laboratory findings, and fluid balance in terminally ill patients with abdominal malignancies. Journal of Pain &amp;amp; Symptom Management 2006;31:130-9.&lt;/p&gt;" NOTES_MODIFIED="2014-04-03 14:46:33 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morita T, Hyodo I, Yoshimi T, Ikenaga M, Tamura Y, Yoshizawa A, et al</AU>
<TI>Artificial hydration therapy, laboratory findings, and fluid balance in terminally ill patients with abdominal malignancies</TI>
<SO>Journal of Pain &amp; Symptom Management</SO>
<YR>2006</YR>
<VL>31</VL>
<PG>130-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2013-12-16 03:38:44 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-04-17 11:20:30 +0100" MODIFIED_BY="Anna Hobson">
<ADDITIONAL_REFERENCES MODIFIED="2014-04-17 11:20:30 +0100" MODIFIED_BY="Anna Hobson">
<REFERENCE ID="REF-Abernethy-2003" MODIFIED="2008-08-06 14:53:44 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Abernethy 2003" TYPE="JOURNAL_ARTICLE">
<AU>Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C</AU>
<TI>Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>523-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ashby-1995" MODIFIED="2008-08-06 14:53:51 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Ashby 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ashby M, Stoffell B</AU>
<TI>Artificial hydration and alimentation at the end of life: a reply to Craig</TI>
<SO>Journal of Medical Ethics</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>3</NO>
<PG>135-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0306-6800 (Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bozzetti-1996" MODIFIED="2014-04-03 14:46:57 +0100" MODIFIED_BY="Anne Lawson" NAME="Bozzetti 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bozzetti F, Amadori D, Bruera E, Cozzaglio L, Corli O, Filiberti A, et al</AU>
<TI>Guidelines on artificial nutrition versus hydration in terminal cancer patients. European Association for Palliative Care</TI>
<SO>Nutrition</SO>
<YR>1996</YR>
<VL>12</VL>
<NO>3</NO>
<PG>163-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Breitbart-2002" MODIFIED="2008-08-06 14:54:03 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Breitbart 2002" TYPE="JOURNAL_ARTICLE">
<AU>Breitbart W, Tremblay A, Gibson C</AU>
<TI>An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients</TI>
<SO>Psychosomatics</SO>
<YR>2002</YR>
<VL>43</VL>
<NO>3</NO>
<PG>175-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casarett-2005" MODIFIED="2008-08-06 14:54:05 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Casarett 2005" TYPE="JOURNAL_ARTICLE">
<AU>Casarett D, Kapo J, Caplan A</AU>
<TI>Appropriate use of artificial nutrition and hydration-fundamental principles and recommendations</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>24</NO>
<PG>2607-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Craig-1994" MODIFIED="2008-08-06 14:54:10 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Craig 1994" TYPE="JOURNAL_ARTICLE">
<AU>Craig GM</AU>
<TI>On withholding nutrition and hydration in the terminally ill: has palliative medicine gone too far?</TI>
<SO>Journal of Medical Ethics</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>3</NO>
<PG>139-43; discussion 144-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0306-6800 (Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dev-2012" MODIFIED="2014-04-16 07:12:39 +0100" MODIFIED_BY="[Empty name]" NAME="Dev 2012" TYPE="JOURNAL_ARTICLE">
<AU>Dev R, Dalal S, Bruera E</AU>
<TI>Is there a role for parenteral nutrition or hydration at the end of life?</TI>
<SO>Current opinion in supportive and palliative care</SO>
<YR>2012</YR>
<VL>6</VL>
<NO>3</NO>
<PG>365-70</PG>
<IDENTIFIERS MODIFIED="2014-04-16 07:12:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22801468"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Doyle-2004" MODIFIED="2014-04-03 14:47:18 +0100" MODIFIED_BY="Anne Lawson" NAME="Doyle 2004" TYPE="BOOK">
<AU>Doyle D, Hanks G, Cherny NI, Calman K</AU>
<SO>Oxford Textbook of Palliative Medicine</SO>
<YR>2004</YR>
<EN>3rd</EN>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Good-2014" MODIFIED="2014-04-17 11:20:30 +0100" MODIFIED_BY="Anna Hobson" NAME="Good 2014" TYPE="COCHRANE_REVIEW">
<AU>Good P, Cavenagh J, Mather M, Ravenscroft P</AU>
<TI>Medically assisted nutrition for adult palliative care patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>4</NO>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2014-04-17 11:17:54 +0100" MODIFIED_BY="Anna Hobson">
<IDENTIFIER MODIFIED="2014-04-17 11:17:54 +0100" MODIFIED_BY="Anna Hobson" TYPE="DOI" VALUE="10.1002/14651858.CD006274.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-04-03 14:48:25 +0100" MODIFIED_BY="Anne Lawson" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2014-04-03 17:14:13 +0100" MODIFIED_BY="Anne Lawson" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lanuke-2003" MODIFIED="2008-08-06 14:54:17 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Lanuke 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lanuke K, Fainsinger RL</AU>
<TI>Hydration management in palliative care settings-a survey of experts</TI>
<SO>Journal of Palliative Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>278-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morita-1998" MODIFIED="2008-08-06 14:54:19 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Morita 1998" TYPE="JOURNAL_ARTICLE">
<AU>Morita T, Ichiki T, Tsunoda J, Inoue S, Chihara S</AU>
<TI>A prospective study on the dying process in terminally ill cancer patients</TI>
<SO>American Journal of Hospital Palliative Care</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>4</NO>
<PG>217-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raijmakers-2011" MODIFIED="2014-04-16 07:02:28 +0100" MODIFIED_BY="[Empty name]" NAME="Raijmakers 2011" TYPE="JOURNAL_ARTICLE">
<AU>Raijmakers NJ, Fradsham S, van Zuylen L, Mayland C, Ellershaw JE, van der Heide A</AU>
<TI>Variation in attitudes towards artificial hydration at the end of life: a systematic literature review</TI>
<SO>Current opinion in supportive and palliative care</SO>
<YR>2011</YR>
<VL>5</VL>
<NO>3</NO>
<PG>265-72</PG>
<IDENTIFIERS MODIFIED="2014-04-16 07:01:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21738035"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rees-2003" MODIFIED="2008-08-06 14:54:22 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Rees 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rees E, Hardy J</AU>
<TI>Novel consent process for research in dying patients unable to give consent</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7408</NO>
<PG>198</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rinck-1997" MODIFIED="2008-08-06 14:54:25 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Rinck 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rinck GC, van den Bos GA, Kleijnen J, de Haes HJ, Schade E, Veenhof CH</AU>
<TI>Methodologic issues in effectiveness research on palliative cancer care: a systematic review</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>4</NO>
<PG>1697-707</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2005" MODIFIED="2014-04-03 14:49:25 +0100" MODIFIED_BY="Anne Lawson" NAME="WHO 2005" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>WHO definition of palliative care</TI>
<SO>www.who.int/cancer/palliative/definition/en/</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-04-17 11:18:50 +0100" MODIFIED_BY="Anna Hobson">
<REFERENCE ID="REF-Good-2008" MODIFIED="2014-04-17 11:18:50 +0100" MODIFIED_BY="Anna Hobson" NAME="Good 2008" TYPE="COCHRANE_REVIEW">
<AU>Good P, Cavenagh J, Mather M, Ravenscroft P</AU>
<TI>Medically assisted hydration for adult palliative care patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-02-14 11:22:16 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-02-14 11:22:16 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006273.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Bruera-2005">
<CHAR_METHODS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Randomised, controlled, double-blind, multicentre trial<BR/>Method of randomisation: truly random<BR/>Study duration: 2 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Participants with a diagnosis of advanced cancer, defined as locally recurrent or metastatic, with no further treatment planned<BR/>An oral intake &lt; 1000 mL/day, as determined by clinical assessment; and evidence of mild-to-moderate dehydration, exhibited by decreased turgor in the subclavicular region lasting &gt; 2 seconds<BR/>Participants had to have &#8805; 1 of the following findings: dry mouth; thirst; decreased volume of urine output, as reported by the patient; a darker colour of urine than usual, in the absence of reasons for jaundice or haematuria; and laboratory values consistent with dehydration, such as an elevated blood urea nitrogen to creatinine ratio of more than 20:1, when this value was obtained within 24 hours of admission to the study<BR/>Participants had to be &gt; 16 years, able to understand and give consent for participation in the study, and able to tolerate parenteral treatment and the application of a subcutaneous or IV cannula</P>
<P>Sample size: 74 (13 were not eligible, 10 refused)<BR/>51 recruited</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>51 patients were randomised to 1 of 2 groups</P>
<OL>
<LI>Intervention: 1000 mL normal saline as an infusion over 4 hours for 2 days (28 recruited, 1 withdrawal)</LI>
<LI>Placebo: 100 mL normal saline as an infusion over 4 hours for 2 days (23 recruited, 1 withdrawal)</LI>
</OL>
<P>Route of administration: IV if IV access available (12 patients); subcutaneous if no IV access (37 patients)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Primary outcome was the global assessment of the overall benefit of hydration to the participant, as determined by the physician and patient on day 2 - no statistically significant difference between groups<BR/>Secondary method of analysis was to test the 2 groups separately to determine whether the proportion of patients perceived to have some benefit was 50% or &gt; 50% - intervention group - P value = 0.0035, placebo group - P value = 0.20<BR/>Target symptoms - numerical rating scale 0-10, with a decrease of 1 point seen as an improvement<BR/>Sedation: more improvement in intervention group (P value = 0.005)<BR/>Fatigue: no difference between groups<BR/>Hallucinations: no difference between groups<BR/>Myoclonus: more improvement in intervention group (P value = 0.035)<BR/>Symptoms totalled together: more improvement in intervention group (P value = 0.06)<BR/>MMSE: no difference</P>
<P>Adverse effects: pain at injection site, injection site swelling: no differences between groups<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Scale score: 5<BR/>Some differences in performance status at randomisation, with intervention group have more participants in performance status 0, I and II</P>
<P>Study was underpowered, as recruitment was less than expected<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Bruera-2013">
<CHAR_METHODS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Randomised, placebo-controlled, double-blind, multicentre study</P>
<P>Method of randomisation: computer-generated simple randomisation scheme</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Advanced cancer (i.e. locally recurrent or metastatic disease) who were:</P>
<UL>
<LI>aged &#8805; 18 years</LI>
<LI>admitted to hospice</LI>
<LI>reduced oral intake of fluids with evidence of mild or moderate dehydration as defined by:</LI>
<UL>
<LI>decreased skin turgor in subclavicular region (2 seconds) and</LI>
<LI>score of &#8805; 2 of 5 in the clinical dehydration assessment</LI>
</UL>
<LI>intensity of &#8805; 1 on a 0 to 10 scale for fatigue and 2 of the 3 other target symptoms (hallucinations, sedation and myoclonus)</LI>
<LI>life expectancy 1 week</LI>
<LI>availability of a primary carer</LI>
<LI>MDAS score &lt; 13</LI>
<LI>ability to give written informed consent</LI>
<LI>geographic accessibility (within 60 miles of the University of Texas MD Anderson Cancer Center)</LI>
</UL>
<P>Sample size: 905 patients assessed for eligibility</P>
<P>Excluded: 776</P>
<P>Included: 129</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>129 patients were randomised to 1 of 2 groups</P>
<OL>
<LI>Parenteral hydration (1000 mL normal saline administered subcutaneously over 4 hours) (63 recruited, 49 completed and analysed)</LI>
<LI>Placebo (100 mL normal saline administered subcutaneously over 4 hours) (66 recruited, 53 completed and analysed)</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Primary outcome:</P>
<OL>
<LI>Change in the sum of 4 dehydration symptoms (fatigue, myoclonus, sedation and hallucinations) between day 4 and baseline - no difference between groups</LI>
</OL>
<P>Secondary outcomes:</P>
<OL>
<LI>Delirium: MDAS - no difference, RASS - no difference, NuDESC - no difference, except night-time NuDESC where placebo group deteriorated more than intervention group (P value = 0.028)</LI>
<LI>Change in the sum of 4 dehydration symptoms (fatigue, myoclonus, sedation and hallucinations) between day seven and baseline: no difference between groups</LI>
<LI>Global symptom evaluation: no difference between groups</LI>
<LI>Quality of life: day 7, using FACIT-F and FACIT-G: no difference between groups</LI>
<LI>Hydration status: using dehydration assessment scale: no difference between groups at day 4 and day 7</LI>
<LI>Survival: median survival 17 days, with no significant difference between groups</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Scale score: 5</P>
<P>Underpowered - powered for 150 patients but recruitment stopped at 129 due to funding limitations</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Cerchietti-2000">
<CHAR_METHODS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Randomised, comparative prospective, single-centre trial<BR/>Method of randomisation: unclear<BR/>Blinding status: unclear<BR/>Study duration: 48 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Terminal stage advanced cancer patients.</P>
<P>&#8805; 1 of the following symptoms: thirst; chronic nausea or delirium; dehydration diagnosed on physical examination, with or without renal failure; and inability to maintain an adequate water intake (&lt; 50 mL/day fluid)<BR/>Sample size: 50<BR/>Exclusions: 4 uncontrolled symptoms (pain in 2 of the participants, severe dyspnoea in 2), 1 bowel obstruction syndrome requiring surgery, 3 severe constipation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>42 patients were randomised to 1 of 2 groups</P>
<OL>
<LI>Treatment (1000 mL 5% dextrose in water infusion with the addition of 140 mEq/L sodium chloride per day, at an infusion rate of 42 mL/hour subcutaneous (20 patients)</LI>
<LI>Usual treatment: no subcutaneous fluids given (22 patients)</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Primary outcomes (VAS):</P>
<OL>
<LI>Thirst</LI>
<LI>Chronic nausea</LI>
<LI>Delirium</LI>
<LI>MMSE</LI>
</OL>
<P>The results were not tabulated, and some graphs were given. The authors stated, "that 1000 ml/day subcutaneous hydration does not improve control of the assessed symptoms when added to the general and pharmacological treatment in patients with end-stage cancer. However, control of chronic nausea after 24 hours was significantly better in the group receiving hydration"<BR/>However, the graph of this actually shows the 2 groups both improving and the non-hydration group improving more in terms of the VAS</P>
<P>Secondary outcomes:</P>
<OL>
<LI>Anguish (measurement not defined): no differences between groups</LI>
<LI>Mood (measurement not defined): no differences between groups</LI>
<LI>Interruption of hydration (oedema, increase in respiratory secretions, congestive heart failure)</LI>
<LI>Local adverse reactions: 1 patient had erythema and pain at puncture site, 36 hours after start of treatment</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Scale score: 2<BR/>Median survival: about 4 days in both groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Morita-2005">
<CHAR_METHODS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Prospective, observational, multicentre study<BR/>Method of randomisation: none<BR/>Study duration: 3 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Age &gt; 20 years; life expectancy estimated by a physician to be &lt; 3 months; and incurable malignancy of abdominal origin (excluding hepatic malignancies)<BR/>Sample size: 498 participants who met the inclusion criteria were consecutively recruited for this study<BR/>Excluded: 272 participants for the following reasons: 200 death within 3 weeks of initial assessment, 35 survival beyond the observation period, 17 medical complications, 15 prior communication difficulty, 5 discharged</P>
<P>Included: 226 patients (49 from oncology units and 177 from palliative/home-care settings)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>226 patients were randomised to 1 of 2 groups</P>
<OL>
<LI>Hydration group (31 from oncology and 28 from palliative/home-care settings) - patients who received artificial hydration of &#8805; 1 L/day both 1 week and 3 weeks before death (59 patients)</LI>
<LI>Non-hydration group (18 from oncology and 149 from palliative/home-care settings) (167 patients)</LI>
</OL>
<P>The mean hydration volume in the hydration group was 838-1405 mL/day during the last 3 weeks, and the median hydration volume in the non-hydration group was 200 mL/day at all 3 observation points</P>
<P>Form of hydration was unclear, but a previous paper described it as IV<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<OL>
<LI>Dehydration: significantly higher in the non-hydration group (35% versus 14%, P value = 0.002)</LI>
<LI>Fluid retention:</LI>
<OL>
<LI>pleural effusion: significantly higher in the hydration group (15% versus 5.4%, P value = 0.016)</LI>
<LI>ascites: significantly higher in the hydration group (29% versus 8.4%, P value &lt; 0.001)</LI>
<LI>bronchial secretions: no significant difference between groups</LI>
<LI>peripheral oedema: significantly higher in the hydration group (44% versus 29%, P value = 0.039)</LI>
</OL>
<LI>Hyperactive delirium: no significant difference between groups</LI>
<LI>Myoclonus: no significant difference between groups</LI>
<LI>Bedsores: no significant difference between groups</LI>
<LI>Degree of communication capacity: no significant difference between groups</LI>
<LI>Degree of agitation between the 2 groups: no significant difference between groups</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Rinck score: 4.5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Viola-1997">
<CHAR_METHODS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Prospective, comparative study<BR/>Multicentre study - Edmonton (hydration group) and Ottawa (no hydration group)<BR/>Method of randomisation: none</P>
<P>Study duration: enrolment until death, no longer having a fluid deficit or discharge from palliative care unit</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Advanced cancer</P>
<P>Phase I: inpatients of either Edmonton or Ottawa palliative care units with advanced cancer, not aphasic, MMSE &gt; 24 and subjectively competent (as judged by physician), able to understand English (Edmonton) or English or French (Ottawa)</P>
<P>Participant at risk of developing a fluid deficit or on admission already having a fluid deficit:</P>
<UL>
<LI>'at risk' defined as history of poor oral fluid intake or excess fluid loss or both</LI>
<LI>'fluid deficit' was defined as being at risk for fluid deficit (as above) plus</LI>
<UL>
<LI>history of decreased urine output, dry mouth sensation, thirst sensation, postural dizziness or combination or</LI>
<LI>resting heart rate &gt; 100 bpm, postural drop in blood pressure &#8805; 10 mmHg on sitting, poor skin turgor over sternum, dry mucous membranes, enophthalmos or combination</LI>
</UL>
</UL>
<P>Exclusions: receiving enteral tube feedings, acute renal failure, pulmonary oedema or bleeding disorder, aphasic, MMSE &lt; 24<BR/>Sample size: 288<BR/>Excluded: 165 (164 with cognitive deficit, 1 with bleeding disorder)<BR/>Consent sought: 123<BR/>Consented Phase I: 94<BR/>Considered for Phase II: 70<BR/>Entered Phase II: 68 (2 excluded as no data collected) leaving 66 participants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>66 patients were randomised to 1 of 2 groups</P>
<OL>
<LI>Edmonton group: subcutaneous fluids (titrated to participant needs) plus usual care. Solutions were usually 0.9% saline or 0.3% saline with 3.3% dextrose. Hyaluronidase 750 units added to each 1 L of fluid solution. The median volume was approximately 1000 mL/day (- 33 patients)</LI>
<LI>Ottawa group: usual care (33 patients)</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>VAS: 12 symptoms - pain, activity, nausea, depression, anxiety, drowsiness, appetite, sense of well-being, dyspnoea, weakness, thirst and dry mouth Assessed by participants or staff depending on ability of participants<BR/>Bowel movements<BR/>Vomiting<BR/>Pressure ulcers<BR/>Peripheral oedema<BR/>Myoclonus<BR/>Level of consciousness<BR/>Delirium Rating Scale<BR/>MMSE<BR/>Oral mucosal assessment</P>
<P>Time spent in Phase II and survival from enrolment in Phase II. The demographics of the groups differed at study entry and there were also many differences in the outcome measures at baseline. Results were only reported as frequency in each group, and there was no statistical analysis performed to determine if there was any significant differences between the groups on any of the measured outcomes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Rinck score 4<BR/>Well-designed study, but the major flaw was that the groups were not matched at study entry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Waller-1994">
<CHAR_METHODS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Prospective controlled, single centre study<BR/>Method of randomisation: none<BR/>Study duration: admission to hospice until death</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Palliative care patients admitted to hospice, in whom blood and urine samples were collected &#8804; 48 hours before death</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>68 patients were randomised to 1 of 2 groups</P>
<OL>
<LI>Oral hydration: volumes not described (55 patients)</LI>
<LI>IV hydration: 1-2 L/day (13 patients)</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>State of consciousness: no significant difference between groups<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Rinck score = 1.5</P>
<P>Methodological problems:</P>
<UL>
<LI>Poorly defined control group</LI>
<LI>No baseline data presented</LI>
<LI>Length of time of IV fluids not stated</LI>
<LI>Nature of IV fluid not stated</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>bpm: beats per minute; FACIT-F: Functional Assessment of Chronic Illness Therapy - Fatigue; FACIT-G: Functional Assessment of Chronic Illness Therapy - General; IV: intravenous; MDAS: Memorial Delirium Assessment Scale; MMSE: Mini Mental State Examination; NuDESC: Nursing Delirium Screening Scale; RASS: Richmond Agitation Sedation Scale; VAS: visual analogue scale.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Morita-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Prospective controlled study examining fluid status of terminally ill cancer patients with intestinal obstruction. Excluded because there was no comparisons between groups with regards to hydration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Morita-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Multicentre, prospective, observational study examining artificial hydration therapy, laboratory findings and fluid balance in terminally ill patients with abdominal malignancies. Excluded because there was no comparison between the symptoms of the hydrated and non-hydrated groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-12-16 03:38:44 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Bruera-2005">
<DESCRIPTION>
<P>"Random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Bruera-2013">
<DESCRIPTION>
<P>"Computer-generated simple randomization scheme"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Cerchietti-2000">
<DESCRIPTION>
<P>States "randomly assigned", but method not adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Morita-2005">
<DESCRIPTION>
<P>Not randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Viola-1997">
<DESCRIPTION>
<P>No randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Waller-1994">
<DESCRIPTION>
<P>Not randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Bruera-2005">
<DESCRIPTION>
<P>"Sealed envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Bruera-2013">
<DESCRIPTION>
<P>"Pharmacist randomly assigned patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Cerchietti-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Morita-2005">
<DESCRIPTION>
<P>Not randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Viola-1997">
<DESCRIPTION>
<P>Groups differed at study entry</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Waller-1994">
<DESCRIPTION>
<P>Not randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-12-17 05:33:24 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Bruera-2005">
<DESCRIPTION>
<P>"Double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Bruera-2013">
<DESCRIPTION>
<P>"Identical backpacks"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Cerchietti-2000">
<DESCRIPTION>
<P>No blinding described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Morita-2005">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Viola-1997">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Waller-1994">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Bruera-2005">
<DESCRIPTION>
<P>Blinding of outcome assessor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Bruera-2013">
<DESCRIPTION>
<P>Research nurse conducting the study assessments was blinded to study intervention and randomisation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Cerchietti-2000">
<DESCRIPTION>
<P>No blinding described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Morita-2005">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Viola-1997">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Waller-1994">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-09 15:06:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruera-2005">
<DESCRIPTION>
<P>All participants accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-17 05:47:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruera-2013">
<DESCRIPTION>
<P>All participants accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Cerchietti-2000">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Morita-2005">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Viola-1997">
<DESCRIPTION>
<P>As treated analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Waller-1994">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Bruera-2005">
<DESCRIPTION>
<P>No problems detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 05:47:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruera-2013">
<DESCRIPTION>
<P>No problems detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Cerchietti-2000">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Morita-2005">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Viola-1997">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Waller-1994">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-02-17 03:09:25 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" NO="9">
<NAME>Size of Study (possible biases confounded by small size)</NAME>
<DESCRIPTION>
<P>low risk of bias (&#8805; 200 participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (&lt; 50 participants per treatment arm)</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-25 14:49:53 +0000" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Bruera-2005">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Bruera-2013">
<DESCRIPTION>
<P>50-199 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-25 14:50:18 +0000" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Cerchietti-2000">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 13:31:01 +0100" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Morita-2005">
<DESCRIPTION>
<P>50-199 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-25 14:50:31 +0000" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Viola-1997">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-25 14:50:37 +0000" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Waller-1994">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2014-04-16 13:35:59 +0100" MODIFIED_BY="Anna Hobson">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-04-16 13:35:59 +0100" MODIFIED_BY="Anna Hobson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAANhCAYAAABzV9qNAABxPElEQVR42uzdD6RV2R///w9jJBlj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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-04-16 13:31:03 +0100" MODIFIED_BY="Anna Hobson" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-04-16 13:31:03 +0100" MODIFIED_BY="Anna Hobson" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAT4AAAIJCAIAAACzzcbvAAAZKElEQVR42u3dvY5cx9HG8QUMGA42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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-04-16 14:06:11 +0100" MODIFIED_BY="Anna Hobson">
<APPENDIX ID="APP-01" MODIFIED="2014-04-16 14:06:11 +0100" MODIFIED_BY="Anna Hobson" NO="1">
<TITLE MODIFIED="2014-04-16 13:32:51 +0100" MODIFIED_BY="Anna Hobson">Search strategies for 2014 update</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-16 14:06:11 +0100" MODIFIED_BY="Anna Hobson">
<P>
<B>CENTRAL (<I>The Cochrane Library</I>)</B>
</P>
<P>#1 MeSH descriptor: [Palliative Care] explode all trees</P>
<P>#2 palliat*:it,ab,kw (Word variations have been searched)</P>
<P>#3 MeSH descriptor: [Terminally Ill] this term only</P>
<P>#4 MeSH descriptor: [Terminal Care] explode all trees</P>
<P>#5 (terminal* near/6 care*):it,ab,kw (Word variations have been searched)</P>
<P>#6 ((terminal* near/6 ill*) or terminal-stage* or dying or (close near/6 death)):it,ab,kw (Word variations have been searched)</P>
<P>#7 (terminal* near/6 disease*):it,ab,kw (Word variations have been searched)</P>
<P>#8 (end near/6 life):it,ab,kw (Word variations have been searched)</P>
<P>#9 hospice*:it,ab,kw (Word variations have been searched)</P>
<P>#10 ("end-stage disease*" or "end stage disease* or end-stage illness" or "end stage"):it,ab,kw (Word variations have been searched)</P>
<P>#11 "advanced disease*":it,ab,kw (Word variations have been searched)</P>
<P>#12 ("incurable illness*" or "incurable disease*"):it,ab,kw (Word variations have been searched)</P>
<P>#13 ("advanced directive*" or "living will*" or "do-not-resuscitate order*"):it,ab,kw (Word variations have been searched)</P>
<P>#14 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13</P>
<P>#15 MeSH descriptor: [Fluid Therapy] this term only</P>
<P>#16 MeSH descriptor: [Dehydration] this term only</P>
<P>#17 (hydrat* or dehydrat* or rehydrat* or (fluid* near/6 therap*) or (fluid* near/6 balance*) or (fluid* near/6 manag*) or hypodermoclysis):it,ab,kw (Word variations have been searched)</P>
<P>#18 #15 or #16 or #17</P>
<P>
<B>MEDLINE (Ovid)</B>
</P>
<P>1 exp Palliative Care/</P>
<P>2 palliat*.tw.</P>
<P>3 Terminally Ill/</P>
<P>4 Terminal Care/</P>
<P>5 (terminal* adj6 care*).tw.</P>
<P>6 ((terminal* adj6 ill*) or terminal-stage* or dying or (close adj6 death)).tw.</P>
<P>7 (terminal* adj6 disease*).tw.</P>
<P>8 (end adj6 life).tw.</P>
<P>9 hospice*.tw.</P>
<P>10 ("end-stage disease*" or "end stage disease* or end-stage illness" or "end stage").tw.</P>
<P>11 "advanced disease*".tw.</P>
<P>12 ("incurable illness*" or "incurable disease*").tw.</P>
<P>13 ("advanced directive*" or "living will*" or "do-not-resuscitate order* ").tw.</P>
<P>14 or/1-13</P>
<P>15 Fluid Therapy/</P>
<P>16 Dehydration/ (9949)</P>
<P>17 (hydrat* or dehydrat* or rehydrat* or (fluid* adj6 therap*) or (fluid* adj6 balance*) or (fluid* adj6 manag*) or hypodermoclysis).tw.</P>
<P>18 15 or 16 or 17</P>
<P>19 14 and 18</P>
<P>20 (2010* or 2011* or 2012* or 2013* or 2014*).ed.</P>
<P>21 19 and 20</P>
<P>
<B>EMBASE (Ovid)</B>
</P>
<P>1 exp Palliative Care/</P>
<P>2 palliat*.tw.</P>
<P>3 Terminally Ill/</P>
<P>4 Terminal Care/</P>
<P>5 (terminal* adj6 care*).tw.</P>
<P>6 ((terminal* adj6 ill*) or terminal-stage* or dying or (close adj6 death)).tw.</P>
<P>7 (terminal* adj6 disease*).tw.</P>
<P>8 (end adj6 life).tw.</P>
<P>9 hospice*.tw.</P>
<P>10 ("end-stage disease*" or "end stage disease* or end-stage illness" or "end stage").tw.</P>
<P>11 "advanced disease*".tw.</P>
<P>12 ("incurable illness*" or "incurable disease*").tw.</P>
<P>13 ("advanced directive*" or "living will*" or "do-not-resuscitate order* ").tw.</P>
<P>14 or/1-13</P>
<P>15 Fluid Therapy/</P>
<P>16 Dehydration/</P>
<P>17 (hydrat* or dehydrat* or rehydrat* or (fluid* adj6 therap*) or (fluid* adj6 balance*) or (fluid* adj6 manag*) or hypodermoclysis).tw.</P>
<P>18 15 or 16 or 17</P>
<P>19 14 and 18</P>
<P>20 (2010* or 2011* or 2012* or 2013* or 2014*).dd.</P>
<P>21 19 and 20</P>
<P>
<B>Science Citation Index (ISI Web of Science)</B>
</P>
<P># 13 295 #12 AND #11</P>
<P># 12 53,258 Topic=((hydrat* or dehydrat* or rehydrat* or (fluid* near/6 therap*) or (fluid* near/6 balance* ) or (fluid* near/6 manag* ) or hypodermoclysis))</P>
<P># 11 37,433 #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1</P>
<P># 10 386 Topic=(("advanced directive*" or "living will*" or "do-not-resuscitate order*"))</P>
<P># 9 412 Topic=(("incurable illness*" or "incurable disease*"))</P>
<P># 8 3,316 Topic=("advanced disease*")</P>
<P># 7 12,963 Topic=(("end-stage disease*" or "end stage disease* or end-stage illness" or "end stage"))</P>
<P># 6 2,135 Topic=(hospice*)</P>
<P># 5 6,392 Topic=((end near/3 life))</P>
<P># 4 1,176 Topic=((terminal* near/6 disease*))</P>
<P># 3 1,527 Topic=((terminal* near/6 ill*))</P>
<P># 2 906 Topic=((terminal* near/6 care*))</P>
<P># 1 14,889 Topic=(palliat*)</P>
<P>
<B>CINAHL (EBSCO)</B>
</P>
<P>S23 S14 AND S22</P>
<P>S22 S15 OR S16 OR S17 OR S18 OR S19 OR S21</P>
<P>S21 (fluid* N6 manag* )</P>
<P>S20 (fluid* N6 balance* )</P>
<P>S19 (fluid* N6 therap*)</P>
<P>S18 hypodermoclysis</P>
<P>S17 (hydrat* or dehydrat* or rehydrat*)</P>
<P>S16 (MH "Dehydration")</P>
<P>S15 (MH "Fluid Therapy")</P>
<P>S14 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13</P>
<P>S13 ("advanced directive*" or "living will*" or "do-not-resuscitate order*")</P>
<P>S12 ("incurable illness*" or "incurable disease*")</P>
<P>S11 "advanced disease*"</P>
<P>S10 ("end-stage disease*" or "end stage disease* or end-stage illness" or "end stage")</P>
<P>S9 hospice*</P>
<P>S8 (end n3 life)</P>
<P>S7 (terminal* N6 disease*)</P>
<P>S6 (terminal* N6 ill*)</P>
<P>S5 (terminal* N6 care*)</P>
<P>S4 (MH "Terminal Care+")</P>
<P>S3 (MH "Terminally Ill Patients+")</P>
<P>S2 palliat*</P>
<P>S1 (MH "Palliative Care")</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_15245_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="15245">
<ADDRESS>
<DEPARTMENT>Palliative Care</DEPARTMENT>
<ORGANISATION>St Vincent&#8217;s Private Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Brisbane</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;5 studies included in previous versions of the review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;1 new study included&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1124 of records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1124 of records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1567 of records identified through database searching (2010-2014)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1116 of records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;7 full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;7 - not randomised controlled trials or prospective controlled studies&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>